Mergers & Acquisitions ·
ENDRA Life Sciences Inc. reported second quarter 2026 financial results and announced a definitive merger agreement…
NDRAENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. reported second quarter 2026 financial results and announced a definitive merger agreement with ASP Isotopes Inc., Noble Africa LLC, and Renergen Limited. Under the transaction, Noble Africa will merge into a subsidiary of ENDRA, surviving as a wholly owned subsidiary, while ENDRA is set to be renamed Noble Africa Inc. The deal includes a concurrent private placement expected to generate approximately $50 million in gross proceeds. Closing is anticipated in the fourth quarter of 2026, subject to stockholder and regulatory approvals. Financially, the company reported net income of approximately $160,000 for the quarter ended June 30, 2026, driven by digital asset gains, compared to a net loss of $1.2 million in the prior year period. Operating expenses totaled $1.5 million, with significant reductions in research and development and sales costs. ENDRA Life Sciences operates in the medical technology industry, pioneering thermoacoustic biomarker imaging for liver disease detection.